Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Among authors: nakano t. Thorac Cancer. 2023 Apr;14(11):1004-1011. doi: 10.1111/1759-7714.14836. Epub 2023 Mar 3. Thorac Cancer. 2023. PMID: 36866788 Free PMC article.
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N, Yamada T, Harita S, Hirai S, Katayama Y, Nakano T, Okura N, Tamiya N, Kaneko Y, Uchino J, Takayama K. Nishioka N, et al. Among authors: nakano t. Respir Med Case Rep. 2018 Oct 6;25:261-263. doi: 10.1016/j.rmcr.2018.10.004. eCollection 2018. Respir Med Case Rep. 2018. PMID: 30310765 Free PMC article.
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K. Tanimura K, et al. Among authors: nakano t. Cancer Lett. 2021 Dec 1;522:119-128. doi: 10.1016/j.canlet.2021.09.018. Epub 2021 Sep 15. Cancer Lett. 2021. PMID: 34534615
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib.
Takeda T, Yamada T, Tanimura K, Nakano T, Ishida M, Tachibana Y, Shiotsu S, Horiuchi S, Hibino M, Okada A, Chihara Y, Takayama K. Takeda T, et al. Among authors: nakano t. Diagnostics (Basel). 2021 Nov 23;11(12):2170. doi: 10.3390/diagnostics11122170. Diagnostics (Basel). 2021. PMID: 34943412 Free PMC article.
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Among authors: nakano t. J Cancer Res Clin Oncol. 2023 Jun;149(6):2475-2482. doi: 10.1007/s00432-022-04125-8. Epub 2022 Jun 23. J Cancer Res Clin Oncol. 2023. PMID: 35737092
5,615 results